Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Infliximab
Remicade
Not routinely available
NICE (TA329 (SMC 374/07))
13/11/2019

Indication

Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

Therapeutic Area

Gastro-intestinal system

Status Description

Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines

Formulation

100mg powder for concentrate solution for infusion

Comments

February 2015 - NICE MTA Advice: SMC Advice 374/07 is superseded by NICE TA329. November 2019 - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.

Link to Advice

TA329 (SMC 374/07)

Advice Published

25/02/2015